UNSPSC 51141507: Phenytoin

This classification denotes a cation channel blocker and anticonvulsant agent with the molecular formula C15H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6158TKW0C5, chemically known as 5,5-dwufenylohydantoina but generally known as phenytoin, which bears US NIH Compound Identifier 1775. European Medicines Agency schedules Phenytoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12211MIG.

UNSPSC 51141507 Phenytoin is a Commodity code covering specific pharmaceutical products, but recent state and local solicitations tagged under this code show minimal direct phenytoin procurement and instead reflect broader pharmaceutical supply chain activity across generic drugs, OTC products, and opioid-response medications. State and local governments buying under this code range from county health departments and state pharmacy benefit programs to multi-state cooperative purchasing alliances that aggregate demand across numerous jurisdictions. The actual work being solicited includes establishing supply contracts for generic and branded pharmaceuticals through authorized wholesaler networks, implementing direct-to-manufacturer prescription programs to improve fulfillment efficiency, and procuring specific medications like naloxone for community health initiatives—indicating that the code captures pharmaceutical sourcing more broadly than phenytoin in isolation.

Issuing bodies include Seminole County, Florida (county health), the Texas Health and Human Services Commission (state agency), and the Minnesota Multistate Cooperative Purchasing Alliance (cooperative purchasing vehicle serving multiple states including Oregon). Recent opportunities span an RFP for generic multi-source pharmaceuticals and OTC products through MMCAP with proposals due March 26, 2026; an RFI from Texas HHS exploring direct-to-manufacturer prescription models with a response deadline of April 3, 2026; and an IFB from Seminole County for naloxone and drug deactivation systems with a response deadline of July 26, 2023. Activity concentrates in Florida, Texas, and the upper Midwest (Minnesota and Oregon), with MMCAP's multi-state framework suggesting broader regional reach. Vendors pursuing opportunities under this code should expect detailed pharmaceutical compliance requirements including FDA certification, cGMP adherence, Drug Supply Chain Security Act compliance, and mandated relationships with major wholesalers; competitive evaluation typically weights price competitiveness heavily (up to 75 percent) alongside administrative capability and data format compliance.